Clinical Applications of PET in Oncology

Radiology

Volumn 231, Issue 2, 2004, Pages 305-332

  Rohren, Eric M ^b   Turkington, Timothy G ^a   Coleman, R Edward ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Breast neoplasms, PET; Gastrointestinal tract, PET; Head and neck neoplasms, PET; Lung neoplasms, PET; Lymphoma, PET; Melanoma; Review

Indexed keywords

CARBON 11; FLUORODEOXYGLUCOSE F 18; GLUCOSE; NITROGEN 13; OXYGEN 15; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82;

ALZHEIMER DISEASE; BREAST CARCINOMA; CANCER RESEARCH; CELL VIABILITY; CLINICAL RESEARCH; COLORECTAL CARCINOMA; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EPILEPSY; ESOPHAGUS CARCINOMA; FOLLOW UP; HEAD AND NECK CANCER; HEART DISEASE; HEART MUSCLE CELL; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; INSTRUMENTATION; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; METABOLISM; NEUROLOGIC EXAMINATION; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RADIOISOTOPE DISTRIBUTION; REVIEW; THYROID CARCINOMA;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MELANOMA; NEOPLASM STAGING; NEOPLASMS; PHYSICS; PROGNOSIS; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 2142641665     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2312021185     Document Type: Review

References (201)

1. Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM. Application of annihilation coincidence detection to transocial reconstruction tomography. J Nucl Med 1975; 16:210-214.
2. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of oradio-pharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19:1154-1161.
3. Warburg O. The metabolism of tumors. London, England: Constabee, 1930.
4. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994; 13:601-609.
5. Adam LE, Karp JS, Daube-Witherspoon ME, et al. Performance of a whole-body PET scanner using curve-plate NaI(Tl) detectors. J Nucl Med 2001; 42:1821-1830.
6. Patton JA, Turkington TG. Coincidence imaging with a dual-head scintillation camera. J Nucl Med 1999; 40:432-441.
7. Casey ME, Nutt R. A multicrystal 2-dimensional BGO detector system for positron emission tomography. IEEE Trans Nucl Sci 1986; 33:460-463.
8. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole-body PET scanner. J Nucl Med 1994; 35: 1398-1406.
9. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. J Nucl Med 1997; 38:1614-1623.
10. Melcher CL. Scintillation crystals for PET. J Nucl Med 2000; 41:1051-1055.
11. Valk PE, Casey ME, Bruckbauer T, et al. Clinical evaluation of an LSO PET system for 3D whole-body FDG imaging (abstr). J Nucl Med 2001; 42:309.
12. Muehllrhner G, Karp JS, Surti S. Design considerations for PET scanners. Q J Nucl Med 2002; 46:16-23.
13. American Cancer Society. Cancer facts and figures 2002, American Cancer Society surveillance research. Available at: www.cancer.org. Accessed February 13, 2004.
14. Hazelrigg SR, Boley TM, Weber D, Magee MJ, Naunheim KS. Incidence of lung nodules found in patients undergoing lung volume reduction. Ann Thorac Surg 1997; 64:303-306.
15. Erasmus JJ, Connolly JE, McAdams HP, Roggli VL. Solitary pulmonary nodules. 1. Morphologic evaluation for differentiation of benign and malignant lesions. RadioGraphics 2000; 20:43-58.
16. Dholakia S, Rappaport DC. The solitary pulmonary nodule: is it malignant or benign? Postgrad Med 1996; 99:246-250.
17. Yankelevitz DF, Henschke CI. Does 2-year stability imply that pulmonary nodules are benign? AJR Am J Roentgenol 1997; 168:325-328.
18. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40:556-565.
19. Imdahl A, Jenkner S, Brink I, et al. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. Eur J Cardiothorac Surg 2001; 20:324-329.
20. Lee J, Aronchick J, Alavi A. Accuracy of F-18 fluorodeoxyglucose positron emission tomography for the evaluation of malignancy in patients presenting with new lung abnormalities: a retrospective review. Chest 2001; 120:1791-1797.
21. Yang SN, Liang JA, Lin FJ, Kwan AS, Kao CH, Shen YY. Differentiating benign and malignant pulmonary lesions with FDG-PET. Anticancer Res 2001; 21:4153-4157.
22. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285:914-924.
23. Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647-1649.
24. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490.
25. Matthies A, Hickson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodutes. J Nucl Med 2002; 43:871-875.
26. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16:1075-1084.
27. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchoalveolar lung carcinoma. J Nucl Med 1998; 39:1016-1020.
28. Marom EM, Sarvis S, Herndon JE II, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 2002; 223:453-459.
29. Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF Jr. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 2000; 175:245-249.
30. Murray JG, Erasmus JJ, Bahtiarian EA, Goodman PC. Talc pleurodesis simulating pleural metastases on 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168: 359-360.
31. Luke WP, Pearson FG, Todd TR, et al. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. J Thorac Cardiovasc Surg 1986; 91: 53-56.
32. Whyte RI. Advances in the staging of intrathoracic malignancies. World J Surg 2001; 25:167-173.
33. Patz EF Jr, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18-FDG in patients with bronchogenic carcinoma. Chest 1995; 108:1617-1621.
34. Farrell MA, McAdams HP, Herndon JE, Patz EF Jr. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology 2000; 215:886-890.
35. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localization of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med 1998; 25:1495-1501.
36. Magnani P, Carretta A, Rizzo G, et al. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg (Torino) 1999; 40: 741-748.
37. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66: 886-892.
38. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803-809.
39. Erasmus JJ, Patz EF Jr, McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168: 1357-1360.
40. Rohren EM, Provenzale JP, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG-PET in patients undergoing whole-body staging of non-CNS malignancy. Radiology 2003; 226: 181-187.
41. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993; 186:37-44.
42. Ginsberg RJ, Vokes EE, Rosenzweig K. Epidemiology of non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001;925-927.
43. Duhaylongsod FG, Lowe VJ, Patz EF Jr, et al. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995; 110:130-139.
44. Changlai SP, Tsai SC, Chou MC, Ho YJ, Kao CH. Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep 2001; 8:337-339.
45. Frank A, Lefkowitz D, Jaeger S, et al. Decision logic for the treatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiat Oncol Biol Phys 1995; 32: 1495-1512.
46. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206:755-760.
47. Gupta NC, Falk PM, Frank AL, Thorson AM, Frick MP, Bowman B. Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebr Med J 1993; 78:30-35.
48. Skibber JM, Minsky BD, Hoff PM. Spread of colorectal cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001; 1229-1230.
49. Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119:647-651.
50. Cady B, McDermott WV. Major hepatic resection for metachronous metastases from colon cancer. Ann Surg 1985; 201: 204-209.
51. Fong Y, Kemeny N, Paty P, Blumgart LH, Cohen AM. Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol 1996; 12:219-252.
52. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996; 171: 21-26.
53. Imdahl A, Reinhardt MJ, Nitzsche EU, et al. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000; 385:129-134.
54. Boykin KN, Zibari GB, Lilien DL, McMil lan RW, Aultman DF, McDonald JC. The use of FDG-positron emission tomography for the evaluation of colorectal metastases to the liver. Am Surg 1999; 65: 1183-1185.
55. Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of metastases. Am J Surg 1999; 178:282-287.
56. Rohren EM, Paulson EK, Hagge RH, et al. The role of F-18-FDG PET in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med 2002; 27:550-555.
57. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-1189.
58. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001; 233:293-299.
59. Doci R, Gennari L, Bignami P, et al. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 1991; 78:797-801.
60. Taylor M, Forster J, Langer B, et al. A study of prognostic factors for hepatic resection for colorectal metastases. Am J Surg 1997; 173:467-471.
61. Hung GU, Shiau YC, Tsai SC, Chao TH, Ho YJ, Kao CH. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer. Anticancer Res 2001; 21:1375-1378.
62. Takeuchi O, Saito N, Koda K, Sarashina H, Nakajima N. Clinical assessment of positron emission tomography for diagnosis of local recurrence of colorectal cancer, Br J Surg 1999; 86:932-937.
63. Tyler DS, Onaitis M, Kherani A, et al. Positron emission tomography scanning in malignant melanoma: clinical utility in patients with stage III disease. Cancer 2000; 89:1019-1025.
64. Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I of II melanoma patients. J Clin Oncol 1999; 17: 976-983.
65. Reintgen D, Rapaport D, Tanabe KK, Ross M. Lymphatic mapping and sentinel node biopsy in patients with malignant melanoma. J Fla Med Assoc 1997; 84:188-193.
66. Pu LL, Cruse CW, Wells KE, et al. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. Plast Reconstr Surg 1999; 104:964-969.
67. Dale PS, Foshag LJ, Wanek LA, Morton DL. Metastasis of primary melanoma to two separate lymph node basins: prognostic significance. Ann Surg Oncol 1997; 4:13-18.
68. Klein M, Freedman N, Lotem M, et al. Contribution of whole body F-18-FDG-PET and lymphoscintigraphy to the assessment of regional and distant metastases in cutaneous malignant melanoma: a pilot study. Nuklearmedizin 2000; 39:56-61.
69. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorode-oxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999; 17:1508-1515.
70. Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 2001; 91:1530-1542.
71. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous melanoma. J Clin Oncol 2001; 19:2674-2678.
72. Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001; 77:237-242.
73. Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med 2000; 44:153-167.
74. Valk PE, Segall GM, Johnson DL, et al. Cost-effectiveness of whole-body FDG PET imaging in metastatic melanoma (abstr). J Nucl Med 1997; 38(P):90.
75. Hoffman JM, Wakin HA, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993; 34:567-575.
76. Villringer K, Jager H, Dichgans M, et al. Differential diagnosis of CNS lesion in AIDS patients by FDG-PET. J Comput Assist Tomogr 1995; 19:532-536.
77. Heald AE, Hoffman JM, Bartlett JA, Waskin HA. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET). Int J STD AIDS 1996; 7:337-346.
78. O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med 1997; 38:1575-1583.
79. Leskinen-Kallio S, Ruotsalainen U, Nägran K, et al. Uptake of carbon-11-methi-onine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32:1211-1218.
80. Rodriguez M, Rehn S, Ahlström H, Sundström C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995; 36:1790-1796.
81. Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12:825-830.
82. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10:1185-1189.
83. Joe A, Hoegerle S, Moser E. Cervical lymph node sarcoidosis as a pitfall in F-18 FDG positron emission tomography. Clin Nucl Med 2001; 26:542-543.
84. Karapetis CS, Strickland AH, Yip D, van der Walt JD, Harper PG. PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis. Ann Oncol 2001; 12: 1485-1488.
85. Taaleb K, Kaiser K, Wieler H. Elevated uptake of F-18 FDG in PET scans in nonmalignant disease. Clin Nucl Med 2000; 25:939-940.
86. Sandherr M, von Schilling C, Link T, et al. Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 2001; 12: 719-722.
87. Schmitz A, Risse JH, Grünwald F, Gassel F, Birsack HJ, Schmitt O. Fluorine-18 fluorodeoxyglucose positron emission tomography findings in spondylodiscitis: preliminary results. Eur SpineJ 2001; 10: 534-539.
88. Stumpe KD, Urbielli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25:721-728.
89. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
90. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987; 28:288-292.
91. Rohren EM, Coleman RE. Comparison of FDG-PET and gallium-SPECT in the staging of lymphoma (abstr). Radiology 1999; 213(P):420.
92. Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94:879-888.
93. Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose positron emission tomography asa as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16:603-609.
94. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91:3340-3346.
95. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999; 40:1407-1413.
96. Hollinger EF, Alibazoglu H, Ali A, et al. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med 1998; 23: 93-98.
97. Sugawara Y, Zasadny KR, Kison PV, Baker LH, Wahl RL. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med 1999; 40:1456-1462.
98. Ulusakarya A, Lumbroso J, Casiraghi O, et al. Gallium scan in the evaluation of post chemotherapy mediastinal residual masses of aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 35: 579-586.
99. Ionescu I, Brice P, Simon D, et al. Restaging with gallium scan Identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients. Med Oncol 2000; 17:127-134.
100. Rehm PK. Gallium-67 scintigraphy in the management: Hodgkin's disease and non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1999; 14:251-262.
101. Cremerius U, Fabry U, Neuerburg J, et al. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma. Nuklearmedizin 2001; 40:23-30.
102. de Wit M, Bohuslavizki KH, Buchert R, Bumann D, Clausen M, Hossfeld DK. 18FDG-PET following treatment as a valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12:29-37.
103. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after firstline chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414-419.
104. Römer W, Hanauske AR, Ziegler S, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998; 91:4464-4471.
105. Talbot JN, Haioun C, Rain JD, et al. [18F]-FDG positron emission tomography in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001; 38:193-221.
106. Yeung H, Macapinlac H, Mazumdar M, Bainss M, Finn R, Larson S. FDG-PET in esophageal cancer: incremental value over computed tomography. Clin Positron Imaging 1999; 2:255-260.
107. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer: comparison with computed tomography. Clin Nucl Med 2000; 25:882-887.
108. Bakheet S, Amin T, Alia AG, Kuzo R, Powe J. F-18 FDG uptake in benign esophageal disease. Clin Nucl Med 1999; 24:995-997.
109. Flamen P, Lerut A, Van Cutsem E, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000; 120:1085-1092.
110. Rice TW, Boyce GA, Sivak MV. Esophageal ultrasound and the preoperative staging of carcinoma of the esophagus. J Thorac Cardiovasc Surg 1991; 101:536-543; discussion 543-544.
111. Saunders HS, Wolfman NT, Ott DJ. Esophageal cancer: radiologic staging. Radiol Clin North Am 1997; 35:281-294.
112. Isonok K, Onada S, Ishikawa T, et al. Studies on the causes of death from esophageal carcinoma. Cancer 1982; 49:2173-2179.
113. Lerut T, Flamen P, Ectors N, et al. Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on primary surgery with extensive lymphadenectomy. Ann Surg 2000; 232:743-752.
114. Kim K, Park SJ, Kim BT, Lee KS, Shim YM. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg 2001; 71: 290-294.
115. Block MI, Patterson GA, Sundaresan RS, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64:770-777.
116. Kato H, Kuwano H, Nakajima M, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002; 94: 921-928.
117. Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998; 53:659-665.
118. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive position emission tomography scans. Ann Thorac Surg 1999; 68:1133-1137.
119. Rice TW. Clinical staging of esophageal carcinoma: CT, EUS, and PET. Chest Surg Clin N Am 2000; 10:471-485.
120. Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998; 78:521-527.
121. Reddy SP, Marks JE. Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: results of bilateral neck plus mucosal irradiation vs. ipsilateral neck irradiation. Int J Radiat Oncol Biol Phys 1997; 37:797-802.
122. Colletier PJ, Garden AS, Morrison WH, et al. Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown site: outcomes and patterns of failure. Head Neck 1998; 20:674-681.
123. Mendenhall WM, Mancuso AA, Parsons JT, et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 1998; 20:739-744.
124. Stokkel MP, Bongers V, Hordijk GJ, van Rijk PP. FDG positron emission tomography in head and neck cancer: pitfall or pathology? Clin Nucl Med 1999; 24:950-954.
125. Mukberji SK, Drane WB, Mancuso AA, et al. Occult primary tumors of the head and neck: detection with 2-(F-18) fluoro-2-deoxy-D-glucose SPECT. Radiology 1996; 199:761-766.
126. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82:1160-1166.
127. AAssar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999; 210:177-181.
128. Kresnik E, Mikosch P, Gallowitsch HJ, et al. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional modalities. Eur J Nucl Med 2001; 28:816-821.
129. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 1997; 22:209-214.
130. Nowak B, Di Martino E, Janicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999; 38:312-318.
131. Di Martino E, Nowak B, Hassan HA, et al. Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg 2000; 126:1457-1461.
132. Greven KM, Williams DW 3rd, McGuirt WF Sr, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001; 23:942-946.
133. Byers RM, Wolf PF, Ballantyne AJ. Rationale for elective modified radical neck dissection. Head Neck Surg 1988; 10:160-167.
134. Giacomarra V, Tirelli G, Papanikolla L, Bussani R. Predictive factors of nodal metastases in oral cavity and oropharynx carcinomas. Laryngoscope 1999; 109: 795-799.
135. Adams S, Baum R, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18F-FDG ET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25:1255-1260.
136. Manolidis S, Donald PJ, Volk P, Pounds TR. The use of positron emission tomography scanning in occult and recurrent head and neck cancer. Acta Otolaryngol Suppl 1998; 534: 1-11.
137. Tepperman BS, Fitzpatrick PJ. Second respiratory and upper digestive tract cancer after oral cancer. Lancet 1981; 2:547-549.
138. Li P, Zhuang H, Mozley PD, et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med 2001; 26:131-135.
139. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in symptomatic patients. Laryngoscope 2000; 110:1493-1497.
140. Lowe VJ, Boyd JH, Dunphy FR, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000; 18:651-658.
141. Zimny M, Wildberger JE, Cremerius U, et al. Combined image interpretation of computed tomography and hybrid PET in head and neck cancer. Nuklearmedizin 2002; 41:14-21.
142. Johnson JT. Proposal of standardization on screening tests for detection of distant metastases from head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2001; 63:256-258.
143. Baltic S. Analysis of mammography trials renews debate on mortality reduction. J Natl Cancer Inst 2001; 93:1678-1679.
144. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET and the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179:765-770.
145. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187:743-750.
146. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14:1848-1857.
147. Scheidhauer K, Scharl A, Pietrzyk U, et al. Qualitative [18F] FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996; 23:618-623.
148. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-(F-18) fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993; 17: 582-589.
149. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495-3502.
150. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998; 39:431-435.
151. Crowe J, Adler L, Shenk R, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994; 1:132140.
152. Utech C, Young C, Winter P. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23: 1588-1593.
153. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18 FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998; 39:4-8.
154. Rostom AY, Powe J, Kandil A, et al. Positron emission tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol 1999; 72:1064-1068.
155. Schirmeister HH, Kuehn T, Buck AK, Reske SN. FDG-PET in preoperative staging of breast cancer (abstr). J Nucl Med 2000; 41(P):297.
156. Yang JH, Nam SJ, Lee TS, et al. Comparison of intraoperative frozen section analysis of sentinel lymph node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 2001; 31:1-6.
157. Bender H, Kirst J, Palmedo H, et al. Value of 18-fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997; 17:1687-1692.
158. Kim TS, Moon WK, Lee DS, et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 2001; 25:829-834.
159. Vranjesevic D, Filmont JE, Meta J, et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 2002; 43:325-329.
160. Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value of [18F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 2001; 234:804-811.
161. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84:2291-2302.
162. Shanker LK, Yamamoto AJ, Alavi AA, Mandel S. The clinical utility of 18FDG PET in the management of iodine-negative thyroid cancer (abstr). J Nucl Med 2000; 31(P):310.
163. Schlüter B, Grimm-Riepe C, Beyer W, Lübeck M, Schirren-Bumann K, Clausen M. Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer. Langenbecks Arch Surg 1998; 383:187-189.
164. Ramos CD, Chisin R, Yeung HW, Larson SM, Macapinlac HA. Incidental focal thyroid uptake on FDG positron emission tomographic scans may represent a second primary tumor. Clin Nucl Med 2001; 26:193-197.
165. Davis PW, Perrier ND, Adler L, Levine EA. Incidental thyroid carcinoma identified by positron emission tomography scanning obtained for metastatic evaluation. Am Surg 2001; 67:582-584.
166. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94:3314-3319.
167. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32:792-797.
168. Keogan MT, Tyler D, Clark L, et al. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol 1998; 171:1565-1570.
169. Sperti C, Pasquali C, Chierichetti F, Liessi G, Ferlin G, Pedrazzoli S. Value of 18-fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas. Ann Surg 2001; 234:675-680.
170. Kalady MF, Clary BM, Clark LA, et al. Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol 2002; 9:799-806.
171. Cremerius U, Wildberger H, Zimny M, Jaksy G, Gunther R, Buell U. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? results of a study in 50 patients. Urology 1999; 54:900-904.
172. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999; 40:1125-1131.
173. Hanson MW, Glantz MJ, Hoffman JM, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991; 15:796-801.
174. Pirotte B, Goldman S, Brucher JM, et al. PET in stereotactic conditions increases the diagnostic yield of brain biopsy. Stereotact Funct Neurosurg 1994; 63:144-149.
175. Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83:918-924.
176. Dhital K, Saunders CA, Seed PT, O'Doherty MJ, Dussek J. [(18)F]fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000; 18:425-428.
177. Okada J, Oonishi H, Yoshikawa K, et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 1994; 8:187-191.
178. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with
179. Nakata B, Chung YS, Nishimura S, et al. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997; 79:695-699.
180. Bender H, Bangard N, Metten N, et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 1999; 18:87-91.
181. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101-2111.
182. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen IA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999; 26:51-56.
183. Brücher B, Weber W, Bauer M, et al. Neoadjuvant therapy of esophageal squamous cell cancer: response evaluation by positron emission tomography. Ann Surg 2001; 233:300-309.
184. Kiffer JD, Berlangieri SU, Scott AM, et al. The contribution of 18F-fluoro-2-deoxyglucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998; 19:167-177.
185. Munley MT, Marks LB, Scarfone C, et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 1999; 23:105-114.
186. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001; 92:886-895.
187. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002; 62:51-60.
188. Mah K, Caldwell CB, Ung YC, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002; 52:339-350.
189. Levivier M, Wikier D, Goldman S, et al. Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: early experience with brain tumorstechnical note. J Neurosurg 2000; 93(suppl 3):233-238.
190. Cai J, Chu JC, Recine D, et al. CT and PET lung image registration and fusion in radiotherapy treatment planning using the chamfer-matching method. Int J Radiat Oncol Biol Phys 1999; 43:883-891.
191. Shinoura N, Nishijima M, Hara T, et al. Brain tumors: detection with C-11 choline PET. Radiology 1997; 202:497-503.
192. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39:990-995.
193. Kobori O, Kirihara Y, Kosaka N, Hara T. Positron emission tomography of esophageal carcinoma using 11C-choline and 18F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 1999; 86:1638-1648.
194. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of 18F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42:1805-1814.
195. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39:1757-1762.
196. Sato N, Suzuki M, Kuwata N, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 1999; 22:210-214.
197. Ribom D, Eriksson A, Hartman M, et al. Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer 2001; 92:1541-1549.
198. Chung JK, Kim YK, Kim SK, et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nud Med Mol Imaging 2002; 29: 176-182.
199. Kole AC, Plaat BE, Hoekstra HJ, Vaalburg W, Molenaar WM. FDG and L-[1-11C]-tyrosine imaging of soft-tissue tumors before and after therapy. J Nucl Med 1999; 40:381-386.
200. Watanabe H, Inoue T, Shinozaki T, et al. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 2000; 27:1509-1517.
201. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43:181-186.